Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A(H5N1) Virus–Associated Acute Lung Injury

Loy, Hayley; Kuok, Denise I. T.; Hui, K.; Choi, Miranda H L; Yuen, Wallace; Nicholls, John M.; Peiris, J S Malik; Chan, Michael C. W.

doi:10.1093/infdis/jiy478

Cited by 109 publications

(107 citation statements)

References 38 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…Those mice in receipt of MSCs following infection showed improved survival rates, lung histopathology and reduced serum and BALF inflammatory cytokine and chemokine concentrations compared to the control group [99]. While most studies explore the potential of BM-derived MSCs, a report comparing their performance versus umbilical cord (UC) derived MSCs in a human alveolar epithelial cell and mouse models of H5N1 infection demonstrated better restoration of alveolar fluid clearance and protein permeability with UC-MSCs [100].…”

Section: Mscs In Pre-clinical Models and Clinical Investigations Of Amentioning

confidence: 99%

The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019

2020

View full text Add to dashboard Cite

More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we battle to curtail the spread of the infection in the absence of specific therapies against coronaviruses and in anticipation of a proven safe and efficacious vaccine. Common with previous outbreaks of coronavirus infections, SARS and Middle East respiratory syndrome, COVID-19 can lead to acute respiratory distress syndrome (ARDS) that arises due to an imbalanced immune response. While several repurposed antiviral and host-response drugs are under examination as potential treatments, other novel therapeutics are also being explored to alleviate the effects on critically ill patients. The use of mesenchymal stromal cells (MSCs) for COVID-19 has become an attractive avenue down which almost 70 different clinical trial teams have ventured. Successfully trialled for the treatment of other conditions such as multiple sclerosis, osteoarthritis and graft versus host disease, MSCs possess both regenerative and immunomodulatory properties, the latter of which can be harnessed to reduce the severity and longevity of ARDS in patients under intensive care due to SARS-CoV-2 infection.

show abstract

Section: Mscs In Pre-clinical Models and Clinical Investigations Of Amentioning

confidence: 99%

The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019

2020

View full text Add to dashboard Cite

show abstract

“…Umbilical cord derived MSC were able to restore the alveolar epithelial cell functions as seen by increased alveolar fluid clearance and decreased protein permeability in avian influenza (H5N1) virus lung injuries in mice models. [112] MSCs are resistant to viral infections, and recently it has been established that intrinsically expressed interferon stimulated genes (ISG) protect stem cells against viral infection. The study demonstrated that induction of intrinsic ISG in human MSCs constitutively increased the expression of antivirals (IFI6, ISG15, CCL2, SAT1, PMAIP1 and IFITM1).…”

Section: Introductionmentioning

confidence: 99%

Stem cell therapy in coronavirus disease 2019: current evidence and future potential

et al. 2021

View full text Add to dashboard Cite

“…These effects have also been observed using conditioned medium and exosomes of UC-MSCs. Notably, UC-MSCs treatment slightly improved survival of A/H5N1-infected mice and significantly improved fluid clearance in the alveolar airspace, compared to BM-MSCs and controls [85].…”

Section: Msc Therapy In Viral Infections: Preclinical and Clinical Apmentioning

confidence: 92%

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Rocha

Oliveira

Noronha

et al. 2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) constitute a heterogeneous population of stromal cells with immunomodulatory and regenerative properties that support their therapeutic use. MSCs isolated from many tissue sources replicate vigorously in vitro and maintain their main biological properties allowing their widespread clinical application. To date, most MSC-based preclinical and clinical trials targeted immune-mediated and inflammatory diseases. Nevertheless, MSCs have antiviral properties and have been used in the treatment of various viral infections in the last years. Here, we revised in detail the biological properties of MSCs and their preclinical and clinical applications in viral diseases, including the disease caused by the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2) infection (COVID-19). Notably, rapidly increasing numbers of MSC-based therapies for COVID-19 have recently been reported. MSCs are theoretically capable of reducing inflammation and promote lung regeneration in severe COVID-19 patients. We critically discuss the rationale, advantages and disadvantages of MSC-based therapies for viral infections and also specifically for COVID-19 and point out some directions in this field. Finally, we argue that MSC-based therapy may be a promising therapeutic strategy for severe COVID-19 and other emergent respiratory tract viral infections, beyond the viral infection diseases in which MSCs have already been clinically applied.

show abstract

Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A(H5N1) Virus–Associated Acute Lung Injury

Abstract: Our results suggest that UC-MSCs are effective in restoring AFC and APP in H5N1-associated ALI and confer functional in addition to practical advantages over conventional BM-MSCs.

Cited by 109 publications

References 38 publications

The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019

The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019

Stem cell therapy in coronavirus disease 2019: current evidence and future potential

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Contact Info

Product

Resources

About